ICOTF - iCo Therapeutics Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0620
0.0000 (0.00%)
At close: 10:52AM EDT
Stock chart is not supported by your current browser
Previous Close0.0620
Open0.0620
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0620 - 0.0620
52 Week Range0.0290 - 0.1070
Volume5,450
Avg. Volume3,282
Market Cap9.069M
Beta (3Y Monthly)2.57
PE Ratio (TTM)N/A
EPS (TTM)-0.0150
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile

    iCo Therapeutics Inc. Announces the Issuance of 41,200,000 Units Pursuant to its Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - August 19, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued 41,200,000 units ("Units") pursuant to a non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 per Unit, for aggregate gross proceeds to the Company of $2,060,000. Each Unit issued pursuant to the Private Placement consists of one common share ...

  • Newsfile

    iCo Therapeutics Provides Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - August 6, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today provided an update with respect to the Company's clinical and regulatory path for its Oral Amphotericin B (Oral Amp B) candidate. During Q2 2019, iCo submitted a plan and further additional materials to an Australian IRB (Institutional Review Board) outlining a proposed multi-center study of up to 90 individuals comparing Oral Amp B to ...

  • Newsfile

    iCo Therapeutics Announces AGM Voting Results

    Vancouver, British Columbia--(Newsfile Corp. - June 28, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the results of voting at its 2019 Annual General Meeting of Shareholders held on June 27, 2019.A total of 20,801,184 common shares were voted in connection with the meeting, representing approximately 19% of the issued and outstanding common shares of the company. Shareholders voted as follows:MotionVoted For% Voted ForVotes Withheld% Votes WithheldAppointment ...

  • Associated Press

    Ico Therapeutics: 1Q Earnings Snapshot

    The Vancouver, British Columbia-based company said it had a loss of less than 1 cent on a per-share basis. In the final minutes of trading on Thursday, the company's shares hit 4 cents. A year ago, they ...

  • Newsfile

    iCo Therapeutics Announces First Quarter 2019 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - May 30, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the Quarter ended March 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "during the first quarter we were able to close a financing with several healthcare focused institutional investors, in ...

  • Newsfile

    iCo Therapeutics Announces 2018 Year End Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - April 30, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "2018 represented a year of significant advances as we entered into a clinical trial for Oral Amphotericin B ...

  • Newsfile

    iCo Therapeutics Inc. Announces the Issuance of 3,600,000 Units Pursuant to its Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - March 5, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a further 3,600,000 units ("Units") pursuant to its previously announced non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 per Unit, for total gross proceeds to the Company of C$180,000 (the "Fourth Tranche"), bringing the total number of Units ...

  • Newsfile

    iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - February 25, 2019) -  iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 14,400,000 units (the "Units") pursuant to its previously announced non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 per Unit, for total gross proceeds to the Company of C$720,000.Each Unit issued pursuant to the Private Placement consists ...

  • Newsfile

    iCo Therapeutics Inc. Announces Upsizing of Non-Brokered Private Placement to $1,250,000 CDN

    Vancouver, British Columbia--(Newsfile Corp. - February 19, 2019) -  iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announces an upsizing of a previously announced Non-brokered private placement to $1,250,000 CDN.Each Unit issued pursuant to the Private Placement consists of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant (a "Warrant") exercisable at $0.075 for 36 months from the date of the closing ...

  • Newsfile

    iCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008)

    Vancouver, British Columbia--(Newsfile Corp. - February 19, 2019) -  iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announces that on Friday February 15, 2019 the Company delivered written notice terminating, with immediate effect, its product sublicense agreement with Immune Pharmaceuticals (IMNP: OTCQB), related to iCo-008 (Bertilimumab). Subsequent to the above noted termination, Immune Pharmaceuticals filed a voluntary petition for bankruptcy in the District of New Jersey on February 17, 2019.https://www.pacermonitor.com/public/case/27133041/Immune_Pharmaceuticals_IncAbout ...

  • Newsfile

    iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - February 11, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 4,000,000 units (the "Units") to a Canadian institutional investor pursuant to its previously announced non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 per Unit, for total gross proceeds to the Company of C$200,000. ...

  • Newsfile

    iCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,000

    Vancouver, British Columbia--(Newsfile Corp. - January 31, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQX: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 3,000,000 units (the "Units") pursuant to the first tranche of a non-brokered private placement (the "Private Placement"). The Company plans to issue up to 15,000,000 Units at a price of $0.05 per Unit for total gross proceeds of $750,000 pursuant to ...

  • Newsfile

    iCo Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - November 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter and nine months ended September 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "This quarter was a period of significant achievement for iCo Therapeutics and its wholly-owned subsidiary, ...

  • Newsfile

    iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study

    Vancouver, British Columbia--(Newsfile Corp. - November 15, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and updated guidance on milestones for two drug candidates.-iCo Therapeutics announces that it now has sufficient drug supply for a proposed mid-staged clinical trial, which may be as large as 90 patients in size, investigating the efficacy and safety study of its oral Amphotericin B (oral Amp B) ...

  • Newsfile

    iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board

    Vancouver, British Columbia--(Newsfile Corp. - October 23, 2018) -  iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced the formation of an oral Amphotericin B clinical advisory board with the appointment of Dr. John Perfect and Dr. David Denning.Stated Dr. Peter Hnik, Chief Medical Officer, "we look forward to working with our clinical advisors as we refine the design of mid staged clinical studies for our oral Amphotericin B candidate. We ...

  • Newsfile

    iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference

    Vancouver, British Columbia--(Newsfile Corp. - September 6, 2018) - iCo Therapeutics ("iCo" or the "Company") (TSXV: ICO) (OTCQB: ICOTF), today announced additional positive pharmacokinetic data from its recent Phase 1 study of its Oral Amphotericin B (Oral Amp B) candidate. Previously the Company reported that Oral Amp B achieved a median Cmax of 28 ng/mL and AUC0-inf of 1030 hr*ng/mL at the lowest dose of Oral Amphotericin B of 100 mg, demonstrating superiority of ...

  • Associated Press

    Ico Therapeutics: 2Q Earnings Snapshot

    The Vancouver, British Columbia-based company said it had a loss of 1 cent per share. In the final minutes of trading on Wednesday, the company's shares hit 8 cents. A year ago, they were trading at 4 ...

  • Newsfile

    iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - August 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter and six months ended June 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "the quarter represented a period of significant achievement for iCo Therapeutics with respect to its two clinical ...